Truist Securities Maintains Buy on Amneal Pharmaceuticals, Raises Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has maintained its Buy rating on Amneal Pharmaceuticals (NASDAQ:AMRX) and raised the price target from $9 to $10.
August 12, 2024 | 12:50 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities has maintained its Buy rating on Amneal Pharmaceuticals and raised the price target from $9 to $10.
The Buy rating and increased price target from a reputable analyst can boost investor confidence and potentially drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100